Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Cytopathol ; 127(12): 771-777, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31756042

ABSTRACT

BACKGROUND: Cell blocks are being used more frequently in cytology for ancillary testing, including molecular diagnostics. There are several different methods of processing cell blocks, with plasma-thrombin being one of the most common. Plasma is a blood-derived product and may be a source of DNA. The aim of this study was to determine whether the plasma used for the plasma-thrombin cell block method has amplifiable DNA that may potentially interfere with molecular testing results. METHODS: Expired bags of fresh frozen plasma were collected from a blood bank. From each sample, DNA was extracted from a 1-mL aliquot with the QIAsymphony MIDI kit (Qiagen). The concentration of DNA was measured on a NanoDrop instrument. The amplifiable DNA quality was assessed by polymerase chain reaction (PCR) with primers to generate amplicons of various sizes. Characterization was performed with the AmpFLSTR Identifiler Plus PCR kit with capillary electrophoresis. RESULTS: Twenty samples from 20 bags were collected. All samples showed amplifiable DNA despite low DNA concentrations in a few cases. PCR amplification revealed the presence of high-quality amplifiable DNA (up to 600 base pairs). DNA was amplified at the 16 loci interrogated in all samples tested with the AmpFLSTR Identifiler Plus PCR kit. CONCLUSIONS: The presence of genomic DNA in plasma may theoretically interfere with results of molecular testing. Particularly in clinical samples with low cellularity, the DNA in plasma may potentially either mask the presence of minute amounts of tumor-derived DNA or lead to a false-positive result.


Subject(s)
Blood Banks/statistics & numerical data , DNA Contamination , DNA Primers/administration & dosage , Plasma , Thrombin/metabolism , DNA Fingerprinting , Female , Humans , Male , Polymerase Chain Reaction/methods , Prospective Studies , Sensitivity and Specificity , Specimen Handling
2.
Eur J Med Genet ; 59(10): 540-5, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27592148

ABSTRACT

Mitochondrial DNA (mtDNA) depletion syndrome manifests as diverse early-onset diseases that affect skeletal muscle, brain and liver function. Mutations in several nuclear DNA-encoded genes cause mtDNA depletion. We report on a patient, a 3-month-old boy who presented with hepatic failure, and was found to have severe mtDNA depletion in liver and muscle. Whole-exome sequencing identified a homozygous missense variant (c.544C > T, p.R182W) in the accessory subunit of mitochondrial DNA polymerase gamma (POLG2), which is required for mitochondrial DNA replication. This variant is predicted to disrupt a critical region needed for homodimerization of the POLG2 protein and cause loss of processive DNA synthesis. Both parents were phenotypically normal and heterozygous for this variant. Heterozygous mutations in POLG2 were previously associated with progressive external ophthalmoplegia and mtDNA deletions. This is the first report of a patient with a homozygous mutation in POLG2 and with a clinical presentation of severe hepatic failure and mitochondrial depletion.


Subject(s)
DNA, Mitochondrial/genetics , DNA-Directed DNA Polymerase/genetics , Intestinal Pseudo-Obstruction/genetics , Liver Failure, Acute/genetics , Mitochondrial Encephalomyopathies/genetics , Base Sequence , Exome/genetics , Humans , Infant , Intestinal Pseudo-Obstruction/complications , Intestinal Pseudo-Obstruction/physiopathology , Liver Failure, Acute/complications , Liver Failure, Acute/physiopathology , Male , Mitochondria/metabolism , Mitochondria/pathology , Mitochondrial Encephalomyopathies/complications , Mitochondrial Encephalomyopathies/physiopathology , Muscular Dystrophy, Oculopharyngeal , Mutation, Missense , Ophthalmoplegia/congenital
SELECTION OF CITATIONS
SEARCH DETAIL
...